Vertical: HealthcareBase Year: 2018
Market Size (2018)
$31.50B
Projected (2025)
$40.31B
CAGR (2016–2025)
23.8%
Key Players
9+
X-linked hypophosphatemia (XLH) is an inherited disorder characterized by low levels of phosphate in the blood. The phosphate levels reduce as it is abnormally processed in the kidneys, which leads to the loss of phosphate through urine (phosphate wasting) and leads to soft and weak bones, causing rickets. XLH is usually diagnosed in childhood, and symptoms include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is caused by mutations in the PHEX gene on the X chromosome, and the inheritance of the X-linked is dominant. The treatment generally involves supplements of phosphate and high-dose calcitriol (an active form of vitamin D) and may also include growth hormones and corrective surgery. The key factors responsible for driving the market are the increasing prevalence rates of XLH, growing awareness about XLH. However, negative psychological and emotional impacts of having X-linked hypophosphatemia, post-operative complications, unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures are hindering the growth of the global X-linked hypophosphatemia market.
The X Linked Hypophosphatemia Market market is projected to grow at a CAGR of 23.8% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global X- linked hypophosphatemia market study includes the market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on treatment, end user, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
Bargaining power of suppliers in the X-linked hypophosphatemia market is moderate to high. In the global X-Linked hypophosphatemia industry, suppliers are the pharmaceutical manufacturers and intermediate original equipment manufacturers (OEMs). There is a moderate number of suppliers in the global X-Linked hypophosphatemia market, thus leading to a high amount of bargaining power in the market.
Bargaining Power of Buyers
The bargaining power of the buyer is moderate for X-linked hypophosphatemia as the tolerance for substandard products and substitutes is less due to the critical role of these drugs in the therapeutics industry. The switching cost from one firm’s products to another seller’s product is low due to high sensitivity, selectivity, and specificity needed in the X-Linked hypophosphatemia drugs, which reduces the bargaining power of buyers. Proprietary nature of cells, coupled with the difficulty in developing a similar substitute product, also reduces the buying power of the buyers. Thus, beginning from scratch in such specialized industries is very difficult, which reduces backward integration chances.
The Threat of New Entrants
The threat of new entrants is moderate in the global X-linked hypophosphatemia market. The global X-linked hypophosphatemia market is a specialized market with high growth potential, requiring high technological knowledge. The global X-linked hypophosphatemia market is also highly sensitive to technological advancements and disruptive innovations. Development of any novel products with even a small advantage over existing products will have a disastrous effect on the existing players. The therapeutics industry has a high capital and research intensity, which raises the bar for market entry, with capital investment in technology being very high. The global X-linked hypophosphatemia market also needs a highly skilled workforce. The research intensity and higher intellectual property utilized in the industry makes a new technology highly disruptive of existing technology and players.
Threat of Substitutes
The threat of substitutes in the global X-linked hypophosphatemia market is low to moderate. X-Linked hypophosphatemia drugs and therapies have poor alternatives as it is difficult to substitute the drugs which have been approved by the FDA. There is no such availability of any synthetic ingredients and biological which are helpful for the treatment of X-linked hypophosphatemia. The low availability of substitutes is expected to boost the growth of the market.
Intensity of Rivalry
The degree of competition in the global X-linked hypophosphatemia market is moderate. The restrained degree of product differentiation among existing players increases the intensity of rivalry in the market. Manufacturing companies are trying to develop cost-effective drugs in order to make product differentiation more affordable in developing regions. Players are engaged in developing a process to lower their manufacturing cost to overcome the competition. Moreover, the players are also developing advanced techniques to differentiate their product from their rivals. The market growth is expected to be low to moderate due to existing rivalry.
Market estimates by geography (2025)
InsightNorth America leads with $29.33B by 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $4.14B | $24.94B | $29.33B | 24.3% | 73% |
| Asia Pacific | $383.10M | $2.26B | $2.62B | 23.8% | 7% |
| Europe | $678.30M | $4.02B | $4.66B | 23.9% | 12% |
| South America | $516.50M | $2.70B | $2.78B | 20.6% | 7% |
| Rest of the World | $178.80M | $910.90M | $919.00M | 19.9% | 2% |
| Total | $5.89B | $34.82B | $40.31B | 23.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on X Linked Hypophosphatemia Market covering market dynamics, competitive landscape, and strategic outlook.
The X Linked Hypophosphatemia Market market is projected to reach $40.31B by 2025, growing at 23.8% CAGR.
X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by mutations in the phosphate regulating endopeptidase homolog (PHEX), X-Linked gene. XLH is also called as X-linked hypophosphatemic rickets, vitamin D-resistant rickets (VDRR), familial hypophosphatemic rickets, or genetic rickets.
The global X-linked hypophosphatemia market is mainly driven by factors such as rising cases of X-linked hypophosphatemia, increasing awareness about XLH and the severity of the disease, and the proactive initiatives for researching the field of XLH. However, the high cost of the drug and limited availability of treatment options may slow down the growth of the market in the future. On the other hand, a recent drug approval by regulatory authorities such as the US FDA, Health Canada, and the European Medical Agency is likely to offer lucrative opportunities for the growth of the market shortly.
The rising demand for XLH treatment options and lucrative growth opportunities have encouraged industry participants to engage in research to manufacture innovative drug candidates. For instance, Crysvita was approved by Health Canada in December 2018. Similarly, in March 2019, Brazil’s National Health Surveillance Agency (ANVISA) approved Crysvita for the treatment XLH in adult and pediatric patients one year and older. In April 2019, the US FDA and European Medicines Agency (EMA) approved Crysvita to be used in the US and Europe. Kyowa Hakko Kirin, Kyowa Kirin International, and Ultragenyx have been collaborating in the development and commercialization of Crysvita globally. Such approvals are likely to fetch a lot of monetary benefits to the manufacturing company and as well as the marketing company in the coming years. The regulatory approvals of Crysvita also create lucrative opportunities for other key companies operating in the market to come up with new drugs, be it similar or generic. The market is also open for research and comparative clinical trials, now that that burosumab is approved for the treatment of XLH. Thus, other companies can take advantage of this opportunity by strengthening their research initiatives.
Burosumab has been approved in several countries and has proven to be very effective for the treatment of XLH in children and adults. But there are a few side-effects associated with the treatment. The administration of this drug sometimes results in adverse reactions at the injection site, such as hives, reddening of the skin, rashes, swelling, bruising, pain, severe itching, and collection of blood outside of a blood vessel (hematoma). Also, it has been advised that the drug should not be taken if the patient has a history related to kidney diseases. Narrowing of the spaces within the spine is a common problem in adults with XLH and burden on the spinal cord has been testified in adults taking Crysvita. Although the drug is quite efficient in tackling XLH in adults and children, the side-effects caused by the drug may hinder the growth of the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 105 companies operating in the X Linked Hypophosphatemia Market market, including revenue, employee count, and market positioning where available.
Showing 105 of 105 companies
Company Headquarter: London, UK Founded: 1856 Workforce: 15000 employees Company Working: Smith & Nephew develops and markets medical devices worldwide. The company operates through four segments, namely, sports medicine, trauma, orthopedic reconstruction, and advanced wound management. The company primarily serves the providers of medical and surgical treatments and services. In 2014, Smith & Nephew acquired ArthroCare to broaden its sports medicine segment. The company has also acquired Healthpoint Biotherapeutics, which specializes in the production of bioactive for advanced wound management. Smith & Nephew has its presence in more than 100 countries and has major manufacturing units in the US, the UK, Switzerland, Germany, and China.
Ultragenyx Pharmaceutical is a biopharmaceutical company. It focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the US. It also focuses on serious, debilitating metabolic, genetic diseases. The company is led by an experienced management team in rare disease therapeutics.
Narang Medical Limited is India's most reputed manufacturer and supplier of medical equipment, hospital furniture, orthopedic implants, and instruments. The company’s products are being used in over 80 countries by healthcare providers and patients. It is the only company in India to have the widest range of implants in both stainless steel and titanium medical grade.
Prospec-Tany Technogene Ltd is an evolving biotech company providing highly purified proteins worldwide which serves the research community with cytokine-related products for cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cell research. It also produces bacterial-derived recombinant proteins for the research community in Israel and internationally.
Validus Pharmaceuticals LLC engages in acquiring, reformulating, and marketing prescription products in specialty therapeutic areas. It offers pharmaceutical medications in the areas of psychiatric, neurologic, and other disorders. The company’s business is based on the acquisition of established products that are FDA-approved and satisfy unmet clinical needs.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
